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Summary
Propentofylline (PPT) is a drug used in the treatment of both vascular de­
mentia and Alzheimer type dementia. Hydroxy-metabolites of propentofylline 
(OHPPT) also demonstrate the same biological activity as the parent compound. 
As steroisomers of HOPPT are not commercially available, we had to produce 
them for pharmacological and pharmacokinetic studies. The aim of this study 
was to find the strains of Saccharomyces cerevisiae yielding enantiomerically pure 
(R)- or (S)-l-(5-hydroxyhexyl)-3-methyl-7-propylxanthin (OHPPT) from PPT. In 
this paper, we present the results of stereoselective reduction of PPT into 
OHPPT when catalysed by whole cells of baker’s and a few strains of wine yeast 
in water and organic solvents.
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1. Introduction
Propentofylline (PPT, 3-methyl-l-(5-oxohexyl)-7-propyl-xan- 
thine) has been reported to be beneficial in the treatment of 
both vascular dementia and Alzheimer type dementia (1-4). PPT 
increases the solubility of lipids by substituting a methyl group 
for a propyl one in position 7 of the purine backbone of pentoxi­
fylline. The pharmacological effects of PPT may be observed in
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Fig. Bioreduction pathway of propentofylline by yeast.
Stimulation of the nerve growth factor, increased cerebral blood flow and inhibition 
of adenosine uptake. PPT also enhances extracellular adenosine concentrations and 
decreases extracellular levels of glutamate in vivo during ischemia (5,6).
To date, despite the known pharmacological effects, few clinical pharmacokinetic 
or metabolism studies of PPT have been reported in the literature. The short 
half-life of PPT at the terminal elimination phase and poor bioavailability, after oral 
administration to rabbits, suggest that this drug undergoes extensive first-pass me­
tabolism in liver. PPT is metabolised in vitro to the racemic compound - 
(±)-l-{5-hydroxyhexyl)-3-methyl-7-propyl-xanthine (HOPPT) (7-10).
Studies have shown that the racemic mixture and the steroisomers of HOPPT 
demonstrate biological activity. Hydroxy-metabolites of PPT inhibited [^HJnitro- 
benzylthioinosyne binding in rat brains with a similar affinity to propentofylline, 
and also inhibited [^HJadenosine uptake by es transport as effectively as propento­
fylline. Since inhibition of adenosine transport appears to be important for the 
neuroprotective effects of PPT, the hydroxy-metabolites may also provide neuro­
protection. As steroisomers of HOPPT are not commercially available, we had to 
produce them for pharmacological and pharmacokinetic studies.
In this paper, we present the results of stereoselective biotransformation of PPT 
to HOPPT when catalysed by whole cells of baker’s and a few strains of wine yeast in 
both water and organic solvents. Alcohol dehydrogenases (YADH’s) in yeast 
{Saccharomyces cerevisiae) play an important role in the reduction of carbonyl func­
tions in aldehydes and ketones (11). YADH has very narrow substrate specificity and 
generally accepts only aldehydes and methyl ketones. It is therefore of only limited 
use in the preparation of the chiral secondary alcohols.
Microbiological reduction with yeast was carried out under non-fermenting con­
ditions. The stereoselectivity of this biotransformation process was determined us­
ing the HPLC technique with a chiral column. It was established that different yeast 
strains favoured the biotransformation of PPT into different enantiomers.
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2. Materials and methods
2.1. Chemicals
Propentofylline was obtained from Intervet GmbH, Germany; n-hexane and 
2-propanol of HPLC grade were purchased from Merck KgaA Darmstadt, Germany. 
Other reagents were all of analytical grade.
2.2. Microorganisms
Five strains of Saccharomyces cerevisiae: KKP13, KKP35, KKP82, KKP295, KKPU 
were obtained from the Collection of Productive Microorganisms, Department of 
Technical Microbiology and Biochemistry in Warsaw, Poland; another two strains: 
L’hirondelle and Wołczyn were taken from Lesaffre Biocorporation in Warsaw, Po­
land; and Krakowskie was obtained from Baker’s Company in Cracow, Poland.
2.3. Chemical synthesis
l-(5-R,S-hydroxyhexyl)-3-methyl-7-propylxanthine (HOPPT) - racemic standard.
This compound was synthesised from PPT using sodium borohydride reduction. 
Briefly, 140 mg (0.5 mmol) of PPT was dissolved in 10 ml of methanol and 160 mg 
(2.5 mmol) of sodium borohydride was added. The mixture was stirred overnight at 
room temperature. The progress of the reaction was followed using thin layer chro­
matography (benzene:acetone 1:1). After solvent evaporation, the reaction product 
was extracted with methylene chloride. The organic layer was washed three times 
with saturated sodium chloride solution and concentrated under reduced pressure. 
The residue was recrystallized from ethyl ether. M.p. 77-79°C; 90% yield; HPLC: tr = 
14.50; 17.25 min;IR(KBr) [cm-i]:3372 (OH), 1699 (CO), 1645 (CO); ’HNMRBOOMHz 
[DMSOde): 6 [ppm]: 0.83 (t, J = 7.2 Hz, 3H, CH^-CH), 1.03 (d, J=6.3 Hz, 3H, CH-CH3), 
1.30 (m, 4H, CH2-CH2-CH2-CH2), 1.50 (m, 2H, CH2-CH2-CH2), 1.78 (q, J=7.4, 4H, CH- 
CH2- CH2), 3.43 (s, 3H, N-CH3), 3.56 (q, J = 5.5 Hz, IH, CH), 3.85 (t,J=7.2 Hz, 2H, 
N-CH2-CH2), 4.21 (t, J=7.1 Hz, 2H, N-CH2-CH2), 4.33 (d, J=7.2 Hz, IH, OH), 8.09 
(s, IH, lm”-H).
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2.4. Microbiological methods
2.4.1. Biotransformation of PPT in an aqueous medium
In a typical experiment, 2 g of wine yeast (KKP) or 5 g of baker’s yeast were sus­
pended in 150 mL of phosphate buffer. After stirring for 30 min at 30°C, 5 g of glu­
cose and 235 mg (1 mmol) of PPT were added. After stirring for 7 days at 30°C, the 
yeast was filtered off. The filtrate was extracted three times with 100 mL of methy­
lene chloride and dried over Na2S04. The residues obtained from the evaporation of 
the solvent were either dissolved in 2 mL 2-propanol for HPLC analysis or purified 
using silica gel chromatography.
2.4.2. Biotransformation of PPT in organic media
Dry baker’s or wine yeast (2 g) was suspended in 25 mL of the organic solvent 
and 2 mL of tridestilled water was added. After the addition of 58 mg (0.25 mmol) of 
PPT the suspension was stirred for 3 days at 27®C. The yeast was then filtered off, 
the solution concentrated in vacuo, and the residue was dissolved in 2.0 mL of 
2-propanol for analytical purposes.
2.5. Methods of analysis
Polarimetry: Measurement of the optical rotation of the products of the 
stereoselective reduction PTX was carried out on a Digital Polarimeter - DIP 2000 
(Jasco Inc., Japan). The optical rotations R- and S-1-(5-hydroxyhexyl)-3-methyl- 
-7-propylxanthine were in accordance with the literature values (11).
Spectroscopy: NMR spectra for the racemic standard and each enantiomer
were recorded using a Varian VM 300 Hz instrument using tetramethylsilane (TMS) 
as an internal standard. The IR spectra were recorded in KBr pellets on a jasco Spec­
trometer FT/lR-410.
High performance liquid chromatography: The identification of the starting ma­
terials and reduction products as well as the yields of transformation and 
enantiomeric excess were determined by HPLC analysis on a Daicel ChiralPack AD 
Column. The high-performance liquid chromatograph (Dionex Corporation, USA) 
consisted of an isocratic solvent delivery system (Dionex HPLC Pump Series P580), 
an inlet equipped with a 20 pL loop and a variable wavelength UV detector (model 
Dionex UVWIS detector UVD 170S/340S), set at 275 nm. The analytical chiral column 
was 250 X 4.6 mm i.d. Daicel ChiralPack AD (Chemical Industries, France). The tem­
perature was set at 25°C. The mobile phase was n-hexane:2-propanol 780:220 per
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IL phase, vacuum-degassed before use, with a flow rate of ImL The analytes 
were disolved in 2-propanol (at a concentration of Img/mL).
Chromatographic characteristics: Chromatographic data are given in Table 1.
Table 1
Chromatc^raphic data
ki k2 a Rs -A(AG°) 0- mol-i)
3.02 4.02 1.33 2.25 630.53
The chromatognęhlc conditions: n-hexane/2-propanol 780/220 (v/?);
flow rate 1.0 mL/min (isocratic); column temperature 25°C; UV detection at 275 nm; injection 20 
The separation factor (a) was expressed as a = k2 /ki, where kj, kj are the retention factors for the first and second elu­
ting enantiotner.
The retention factors ki and k2 were calculated as follows:
hi = (t*i - to) / to and k2 = (tn2-to) / to, where to, tRi and t*2 are the dead elution times of enantiomers.
The resolution (lO of the first and second eluting enantiomers was calculated by the ratio of the difference between the elu­
tion times tm and tR2 to the arithmetic mean of the two peaks’ widhts wi and W2.
R, = 2(tR2 - tRi) / (wi + W2)
The difference in the free energy (-A(AG°)) was calculated from the separation factor according to the following equ- 
ation:-A(AG“) = RT Ina
3. Results and discussion
l-(5-Oxohexyl)-3-methyl-7-propylxanthine (PPT) was reduced with NaBH4 to 
R,S-l-(5-hydroxyhexyl)-3-methyl-7-propylxanthine (HOPPT), which was used as the 
reference standard in further analytical studies.
The aim of this study was to find the strains of Saccharomyces cerevisiae yielding 
enantiomerically pure (R)- or (S)-l-(5-hydroxyhexyl)-3-methyl-7-propylxanthine from 
PPT. Microbiological reduction using yeast was carried out under non-fermenting 
conditions. In Table 2, a summary of the results obtained using aqueous and organic 
media is given. PPT was reduced using baker’s yeast (Saccharomyces cerevisiae: strains 
- L’hirondelle, Wołczyn and Krakowskie), in an aqueous medium according to 
Prelog’s rule (12) to give an (S)-alcohol with a good optical purity only in the case of 
the L’hirondelle strain, with an ee of 78% for the (S) enantiomer. Bioreductions using 
baker’s yeast were also performed in organic solvents such as ethyl acetate and 
n-hexane. Table 2 shows that in several cases such reductions can be carried out 
quite successfully. However, in organic media yields of the reduction of PPT to 
HOPPT were quite low (from 1 to 23%). In ethyl acetate, all the baker’s strains pre­
ferred to form an (S) isomer, whereas in the n-hexane L’hirondelle strain an (R) iso­
mer was preferred. Drastic solvent dependent ee variations were found for the re­
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duction of PPT using the L’hirondelle strain: 78% ee in favour of the (S) enantiomer 
in water and 100% ee favouring the (R) enantiomer in n-hexane.
Enantioselective bioreduction of propentofylline using yeast in water and organic solvents
Table 2
Bloconversion of PPT to OHPPT In water and in organic solvents
Strains
Yields in water Yields in AcOEt Yields in n-hexane
[%] ee[%] l%] ee[%] [%] ee[%]
KKP 13 32 9 (R) nd nd
KKP 35 48 50 (R) nd nd
KKP 82 94 67 (R) nd nd
KKP 295 75 31 (S) nd nd
KKPU 59 14 (R) nd nd
L’hirondelle 67 78 (S) 10 100 (S) 1 100 (R)
Wołczyn 37 42 (S) 23 100 (S) 2 100 (S)
Krakowskie 41 44 (S) 1 100 (S) 1 100 (S)
nd: not determined
PPT was also bioreduced in the presence of wine yeast in an aqueous medium 
contrary to Prelog’s rule to give the (R)-alcohol, as is the case with reduction using 
LKADH (alcohol dehydrogenase from Lactobacillus kefiri) (13,14). The bio­
transformation of PPT in water using wine yeast gave (R) HOPPT with variable 
enantiomeric excesses (ees from 14 for KKPU to 67% for KKP82), and yields ranging 
from 32 to 94%. Only in the case of biotransformation with KKP295, an (S) isomer 
(ee=31%) was obtained. The KKP82 strain was found to most favour the production 
of (R) HOPPT.
4. Conclusions
The above results demonstrate that the reduction of PPT in ethyl acetate with 
the yeast strain Wołczyn offers a new highly stereoselective method of 
(S)-l-(5-hydroxyhexyl)-3-methyl-7-propylxanthine preparation. Other reduction con­
ditions employed were less effective.
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